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Pulmonary arterial hypertension is most often diagnosed in its advanced stages because of the nonspecific
nature of early symptoms and signs. Although clinical assessment is essential when evaluating patients
with suspected pulmonary arterial hypertension, echocardiography is a key screening tool in the diagnostic
algorithm. It provides an estimate of pulmonary artery pressure, either at rest or during exercise, and is useful
in ruling out secondary causes of pulmonary hypertension. In addition, echocardiography is valuable in
assessing prognosis and treatment options, monitoring the efficacy of specific therapeutic interventions,
and detecting the preclinical stages of disease. (J Am Soc Echocardiogr 2012;-:---.)
Keywords: Echocardiography, Pulmonary hypertension, Exercise-induced pulmonary hypertensionPulmonary hypertension (PH) is a hemodynamic and pathophysio-
logic condition defined as an increase in mean pulmonary artery pres-
sure (MPAP) of $25 mm at rest as assessed by right-heart
catheterization (RHC). It can be found in multiple clinical conditions
with distinct pathogenetic and clinical features, such as pulmonary ar-
terial hypertension (PAH) and left-heart, lung, and thromboembolic
diseases (Table 1).1,2 In particular, PAH is characterized by the
presence of precapillary PH due to relative blood flow obstruction
proximal to the lung capillary bed and increased pulmonary
vascular resistance (PVR). This results in right ventricular (RV)
pressure overload, ultimately leading to right-heart failure and death.
PAH has an estimated prevalence of 30 to 50 cases per million indi-
viduals, affects women more frequently than men, and can be idio-
pathic, heritable, drug or toxin induced, or associated with other
medical conditions, such as congenital heart disease (CHD), connec-
tive tissue disease, human immunodeficiency virus infection, portal
hypertension, schistosomiasis, and chronic hemolytic anemia
(Table 2).3
Given the nonspecific symptoms and subtle physical signs, particu-
larly in the early stages, a high clinical index of suspicion is necessary
to detect the disease before irreversible pathophysiologic changes oc-
cur. In this regard, transthoracic echocardiography, by providing direct
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rg/10.1016/j.echo.2012.10.009an excellent noninvasive screening test for patients with symptoms or
risk factors for PH, such as connective tissue disease, anorexigen use,
pulmonary embolism, heart failure, and heart murmurs. It may also
provide key information on both the etiology and the prognosis
of PH.4-6
In this review, we discuss the diagnostic and prognostic role of
echocardiography in PAH.PULMONARY HEMODYNAMICS IN THE
ECHOCARDIOGRAPHY LAB
Table 3 lists Doppler echocardiographic indices for the evaluation of
patients with clinical suspicion of PH.7-26 Doppler echocardiography
enables the reliable estimation of PAP, because in the absence of
pulmonary flow obstruction, tricuspid regurgitation (TR) peak
velocity (TRV) and RV outflow tract acceleration time have linear
positive and negative correlations, respectively, with systolic PAP
(SPAP) and MPAP measured by RHC.7-12,15-20,27 Furthermore,
peak early diastolic and end-diastolic velocities of pulmonary regurgi-
tation correlate significantly with MPAP and pulmonary artery end-
diastolic pressures.17,18
PVR may be estimated by dividing TRV (in meters per second) by
the time-velocity integral of the RVoutflow tract (in centimeters).21,22
The rationale for this method is based on the recognition that PVR is
directly related to pressure changes and inversely related to
pulmonary flow. This approach may have utility in distinguishing
high PAP due to increased pulmonary blood flow (as occurs in
hyperthyroidism, anemia, and obesity) from PH due to elevated
PVR. An estimate of PVR may also be valuable for identifying
patients with clinically worsening and severe PAH with no change
or a decrease in MPAP as a consequence of progressive decrease in
RV ejection fraction and stroke volume (PVR = MPAP 
pulmonary artery occlusion pressure/cardiac output [CO]). TRV is
used in daily practice to determine RV systolic pressure, which is
considered equal to SPAP in the absence of pulmonary outflow
tract obstruction and/or pulmonic valve stenosis. This is done by
calculating the systolic transtricuspid gradient using the modified
Bernoulli equation (as simplified by Hatle et al.9) and then adding1
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- 2012an assumed or calculated right
atrial pressure (RAP).9-12 Several
studies have shown modest to
good correlations between
estimated RV systolic pressure
and invasively measured
pressures (R = 0.57–0.93),
suggesting that technical and
biological variability are not
negligible. This variability is
further reflected in the
sensitivity (0.79–1.00) and
specificity (0.60–0.98) for
diagnosing or ruling out PH.28-31
However, to avoid false-
positives, it is important to be
aware that the resting physio-
logic range of SPAP is dependent
on age and body mass index and
may be as high as 40 mm Hg in
older (age > 50 years) or obese
(body mass index > 30 kg/m2)
subjects.32 The age-related in-
crease in SPAP is more common
in patients with diabetes and is
likely due to pulmonary artery
noncompliance or abnormal left
ventricular (LV) diastolic filling
pressures occurring with aging
and systemic hypertension. An
increase in SPAP has a negative
impact on survival.33 Moreover,
it should not be overlooked that
SPAP is a flow-dependent vari-
able, such as in anemia and
hypothyroidism, as a TRV of
3 m/sec is easily achieved in nor-
mal subjects at rest after dobut-
amine infusion.34
A few aspects must be kept in
mind to ensure accurate esti-
mates of SPAP. Because velocity
measurements are angle depen-
dent, TRV should be taken
from multiple views (and offaxis if necessary), searching for the best envelope and maximal veloc-
ity. Additionally, the use of color flow Doppler is recommended to
obtain the best alignment between regurgitant flow and the
Doppler signal. From the apical position, the transducer must be an-
gled more medially and inferiorly from the mitral valve signal.
Although TR is present in >75% of the normal adult population, in
case of a trivial regurgitant jet and a suboptimal continuous-wave
Doppler spectrum, the injection of contrast agents (agitated saline,
sonicated albumin, air-blood-saline mixture) may be required to
achieve clear delineation of the jet envelope.35,36 Potential
overestimation of Doppler velocities should be taken into account
because of contrast artifacts. Furthermore, in severe TR with a large
color flow regurgitant jet, the peak velocity may not reflect the true
RV–right atrial pressure gradient because of early equalization of
RV pressure and RAP. Thus, it is recommended to gather
technically adequate TR signals and to consider SPAP values in thecontext of the clinical scenario, searching for other ‘‘concordant
clinical and echocardiographic signs’’ of pressure overload (Table 3).
In this regard, the European Society of Cardiology guidelines for
the diagnosis and treatment of PH suggest to consider (1) PH unlikely
for TRV # 2.8 m/sec, SPAP # 36 mm Hg (assuming RAP of 5 mm
Hg), and no additional echocardiographic signs of PH; (2) PH possible
for TRV# 2.8 m/sec and SPAP# 36 mmHg but the presence of ad-
ditional echocardiographic signs of PH or TRVof 2.9 to 3.4m/sec and
SPAP of 37 to 50 mm Hg with or without additional signs of PH; and
(3) PH likely for TRV > 3.4 m/sec and SPAP > 50 mm Hg with or
without additional signs of PH.2ECHOCARDIOGRAPHIC FEATURES IN PULMONARY
ARTERIAL HYPERTENSION
Figure 1 and Table 3 describe echocardiographic features in PAH.
Because of chronic RV pressure overload, at the time of diagnosis,
most patients present with enlarged right-side chambers, RV hyper-
trophy, increased interventricular septal thickness, an abnormal inter-
ventricular septum/posterior LV wall ratio (>1), and reduced global
RV systolic function. Furthermore, the abnormal pressure gradient be-
tween the left and right ventricles results in shape distortion and mo-
tion of the interventricular septum (‘‘flattening’’), which persists
throughout the cardiac cycle.35 As a consequence, the left ventricle
appears D-shaped, with reduced diastolic and systolic volumes but
preserved global systolic function.6 Pericardial effusion and mitral
valve prolapse have also been described in patients with PAH; the for-
mer may be a manifestation of impaired venous and lymphatic drain-
age secondary to elevated RAP, and the latter is related to a small left
ventricle and the possible involvement of valve leaflets affected by as-
sociated connective tissue disorders.37
At the time of definitive diagnosis, most patients with PAH show at
least moderate TR, with SPAP$ 60 mm Hg. TR is usually caused by
tricuspid annular dilation, altered RV geometry, and apical displace-
ment of the tricuspid leaflets. The degree of TR cannot be used as
a surrogate for the degree of PAP elevation.38
Significant pulmonic valvular regurgitation is common in PAH.
Pulsed-wave Doppler interrogation of the RVoutflow tract usually re-
veals an acceleration time of <100 msec, which reflects abnormal
MPAP.6-8,20 Finally, as a result of altered RV-LV interaction, LV dia-
stolic dysfunction may be characterized by a marked dependence
of LV filling on atrial contraction.39,40TRANSESOPHAGEAL ECHOCARDIOGRAPHY
Transesophageal echocardiography should be considered in the fol-
lowing circumstances: (1) to confirm and assess congenital
systemic-to-pulmonary shunts, (2) to assess the severity and contribu-
tion of mitral valve disease, (3) to characterize a right-sided intracar-
diac mass not well visualized with transthoracic echocardiography
or other imaging techniques, and (4) to guide interventional proce-
dures, such as balloon atrial septostomy.36EXERCISE-INDUCED PULMONARY HYPERTENSION:
LOOKING BEYOND THE SCENE
The pulmonary circulation is a high-flow, low-pressure, low-resistance
system. PVR is approximately one tenth of comparable systemic
Table 1 Hemodynamic definitions of PH
Definition Characteristics Clinical group(s)*
PH MPAP $ 25 mm Hg All
Precapillary PH MPAP $25 mm Hg
PCWP #15 mm Hg
CO normal or reduced†
1. PAH
3. PH due to lung disease
4. Chronic thromboembolic PH
5. PH with unclear and/or multifactorial mechanisms
Postcapillary PH MPAP $ 25 mm Hg
PCWP > 15 mm Hg
CO normal or reduced†
2. PH due to left-heart disease
Passive TPG # 12 mm Hg
Reactive (out of proportion) TPG > 12 mm Hg
TPG, Transpulmonary pressure gradient (MPAP  mean PCWP).
Values are measured at rest. Reproduced with permission from Galie et al.2
*As defined in Table 2.
†High CO can be present in hyperkinetic conditions, such as systemic-to-pulmonary shunts (only in the pulmonary circulation), anemia,
hyperthyroidism, and so on.
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Bossone et al 3values. In healthy subjects, moderate exercise induces mild increases
in PAP that are linear with CO and decreases in PVR secondary to the
dilation of compliant small vessels and/or the recruitment of addi-
tional vessels in the upper portion of normal lungs.41-43
In elite athletes, substantial increases in PAP have been shown to
occur during intense exercise as a result of marked increases in pul-
monary blood flow along with increases in LV filling pressure.44,45
This ‘‘physiologic counteraction’’ may cause an impairment of the
integrity of the pulmonary blood-gas barrier (pulmonary capillary
‘‘breaking stress’’), with the development of exercise-induced pulmo-
nary hemorrhage.45,46 Reported upper normal limits of Doppler-
derived SPAP during exercise are <40 to 45 mm Hg in normal
healthy individuals and <55 to 60 mm Hg in highly trained ath-
letes.8,45,47,48 It is worth noting that PVR varies from one subject to
another. Accordingly, the increase in PAP as a function of CO
during exercise is quite variable as well, with reported slopes of PAP
as a function of flow ranging from 0.5 to 2.5 mm Hg/L/min.49,50
There has been recent suggestion that steep increases in PAP may
be a limiting factor for exercise capacity because of persistent
limitations in RV output.49,51 Competitive athletes who exercise at
high levels of CO and PAP because of an intrinsically steep
pressure-flow relationship may be exposed in the long term to RV re-
modeling and subsequent arrhythmias.52
A number of investigators have reported subsets of patients with
pathologic SPAP responses during exercise and normal SPAP at
rest; this is referred to as exercise-induced PH (Table 4).48,53-64
Recently, using invasive maximum cardiopulmonary exercise
testing, Tolle et al.65 carefully phenotyped a large cohort of patients
with exercise-induced PAH. In particular, they showed that at maxi-
mum exercise, oxygen uptake was lowest in resting PAH, intermedi-
ate in exercise-induced PAH, and highest in normal subjects, whereas
MPAP and PVR followed the opposite pattern. These findings suggest
that exercise-induced PAH is a mild, intermediate physiologic stage of
PAH, with greater vasodilator reserve and less severe degrees of pul-
monary vascular disease.66 However, exercise-induced PAH is rarely
considered because of the lack of specific symptoms or signs. Exercise
Doppler echocardiographic evaluation should be performed in pa-
tients with modest changes in exercise capacity with no other identifi-
able causes, particularly in asymptomatic or mildly symptomatic
subjects at high risk for PAH (i.e., first-degree relatives with PAH,carriers of the PAH gene, patients with human immunodeficiency vi-
rus infection, and patients with connective tissue diseases). Although
exercise Doppler echocardiography has been proved to be a safe and
viable screening tool for detecting a pulmonary hypertensive re-
sponse to exercise in high-risk patients, it remains technically demand-
ing and requires considerable experience. It should also be
emphasized that the optimal exercise protocol (treadmill vs supine,
upright, or semirecumbent bicycle) has not been established.
Importantly, data derived during or after bicycle exercise should not
be applied to posttreadmill or recumbent exercise stress echocardiog-
raphy, because each protocol is characterized by different loading
conditions. However, in the assessment of PH, exercise must be dy-
namic (cycling or walking) rather than resistive (handgrip, weight lift-
ing). Resistive exercise should be avoided because it results in
decreased venous return during the Valsalva maneuver and little
change in maximal oxygen uptake and CO but increased systemic
vascular resistance and an eventual increase in intrathoracic pressure,
each of which may contribute to elevated MPAP at any given level of
flow.67 A resistive component at high levels of dynamic exercise may
spuriously increase MPAP at given levels of CO. Although the results
of MPAPon exercise are often expressed for a given workload, results
of exercise hemodynamics might be better expressed in MPAP as
a function of flow (e.g., millimeters of mercury per liter) rather than
as a function of workload, given that the mechanical efficiency of
muscle contraction varies from one subject to another.68 Recently,
Argiento et al.,50 in a series of 113 healthy volunteers (mean age,
37613 years; range, 19–63 years; 57 women [50%]) reported exer-
cise flow-corrected upper limits of normal for MPAP of 34 mm Hg at
a CO of <10 L/min, 45 mm Hg at a CO of <20 L/min, and 52 mm
Hg at a CO of <30 L/min. All subjects underwent exercise echocar-
diographic testing on a semirecumbent cycle ergometer with work-
load increments of 20 to 30 W every 2 min until the maximum
tolerated before the onset of dyspnea and/or leg pain.
Echocardiographic measurements were taken during the last minute
of each workload.
Thus, at present, semirecumbent exercise appears to be more suit-
able than treadmill exercise for reliable and reproducible Doppler
echocardiographic recordings, given that measures are obtained dur-
ing both exercise and recovery.47,50,69 Furthermore, the full
physiologic range of PAP response to exercise should be defined in
Table 2 Updated clinical classification of PH (Dana Point,
2008)
1. PAH
1.1. Idiopathic
1.2. Heritable
1.2.1. BMPR2
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic
telangiectasia)
1.2.3. Unknown
1.3. Drug and toxin induced
1.4 Associated with
1.4.1. Connective tissue diseases
1.4.2. HIV infection
1.4.3. Portal hypertension
1.4.4. Congenital heart disease
1.4.5. Schistosomiasis
1.4.6. Chronic hemolytic anemia
1.5. Persistent PH of the newborn
1. Pulmonary veno-occlusive disease and/or pulmonary capillary
hemangiomatosis
2. PH due to left-heart disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Valvular disease
3. PH due to lung disease and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and
obstructive patterns
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension
5. PH with unclear and/or multifactorial mechanisms
5.1. Hematologic disorders: myeloproliferative disorders,
splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell
histiocytosis, lymphangioleiomyomatosis, neurofibromatosis,
vasculitis
5.3. Metabolic disorders: glycogen storage disease,
Gaucher disease, thyroid disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis,
chronic renal failure on dialysis
ALK1, activin receptor–like kinase type 1; BMPR2, bone morphoge-
netic protein receptor type 2; HIV, human immunodeficiency virus.
Reproduced with permission from Simonneau et al.3
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Well-designed longitudinal studies are warranted to investigate the
natural history of exercise-induced PAH andwhether preclinical treat-
ment can prevent the development of more severe forms of pulmo-
nary vascular disease in susceptible persons.70,71 Exercise-induced
PAH remains a fascinating clinical condition and exercise Doppler
echocardiography a versatile tool ‘‘to look beyond the scene’’ of other-
wise unexplained effort dyspnea.ECHOCARDIOGRAPHY AND PROGNOSIS
PAH is a progressive disease with a relatively poor prognosis even in the
modern era (reported overall survival rates are 87% [95%CI, 84%–90%], 76% [95% CI, 73%–80%], and 67% [95% CI,
63%–71%] at 1, 2, and 3 years, respectively).72 The natural history
is heterogeneous and influenced mostly by ‘‘treatability’’ and/or ‘‘re-
versibility’’ of the underlying etiology, with systemic sclerosis and por-
topulmonary hypertension having the worst and CHD the best
prognosis (neonatal right ventricles may also adapt better to increased
PVR).1,2,73,74
Before treatment, patients with suspected PAH should have confir-
mation of the diagnosis by exclusion of other causes of PH with RHC
and/or left-heart catheterization, including both Fick and thermodilu-
tion estimates of CO. Although PAH is common in systemic sclerosis,
about 50% of patients with PHwill exhibit significant LV diastolic dys-
function and elevated LVend-diastolic pressure. Pulmonary capillary
wedge pressure (PCWP) and pulmonary artery occlusion may be in-
accurate in patients with more than mild to moderate PH. A careful
and comprehensive prognostic evaluation in patients with PAH
should include indices of impaired clinical status (World Health
Organization [WHO] functional classes I–IV), exercise capacity as
measured by standardized 6-min hall walk or cardiopulmonary exer-
cise test, biomarkers such as B-type natriuretic peptide, renal function,
Doppler echocardiography, and possibly magnetic resonance imag-
ing. Each of these can correlate with gold-standard findings on cardiac
catheterization. All of these parameters are indicators of significant
right-heart dysfunction and are associated with unfavorable outcomes
(death or lung transplantation) in patients with PAH.2
Echocardiographic predictors of prognosis include pericardial effu-
sion, indexed right atrial area, the degree of septal shift toward the
left ventricle in diastole, tricuspid annular plane systolic excursion,
pulmonary vascular capacitance, and RV Doppler index (Tei index
or RV myocardial performance index) (Table 5).14,37,75-82 In a series
of 53 patients with PAH (38 women; mean age, 45 6 14 years), at
a mean follow-up of 2.9 years, the RV Doppler index, a measure of
global RV function, was a strong predictor of adverse outcomes on
univariate and multivariate regression analysis.77NONCONVENTIONAL ECHOCARDIOGRAPHY
The accuracy of conventional two-dimensional (2D) echocardiogra-
phy in delineating RV structure and function is challenged by several
factors, including (1) the asymmetric and complex pyramidal shape of
the right ventricle, along with its retrosternal location; (2) limited def-
inition of the endocardial surface; and (2) marked load dependence
of many functional indices.83-86 Emerging ultrasound techniques,
namely, Doppler tissue imaging, strain imaging, and real-time three-
dimensional echocardiography (RT3DE), may provide additional in-
formation (Figure 2).87-90Doppler Tissue Imaging
Doppler tissue imaging of the mitral and tricuspid annulus has been
extensively applied to assess LV and RV function in many cardiac dis-
eases, including CHD, heart failure, and PH.91-95
According to the current American Society of Echocardiography
guidelines on right-heart assessment, basal RV free wall S0 <
10 cm/sec should be considered a marker of RV dysfunction, partic-
ularly in young adults (no sufficient data exist in the elderly).8,96,97
Specifically, Ruan and Nagueh,98 in a series of 70 patients with id-
iopathic PAH (IPAH), demonstrated that lateral mitral annular veloc-
ities can reliably predict the presence of normal or reduced mean
PCWP, ruling out ‘‘de facto’’ a left-heart etiology. In addition, tissue
Doppler analysis of systolic and diastolic myocardial velocities may
Table 3 Doppler echocardiographic indices for the evaluation of patients with clinical suspicion of PH7,8
Key indices (cutoff) Additional indices (cutoff) Complementary indices (cutoff) Research tools
Pulmonary hemodynamics
SPAP = 4  TRV2 + RAP9-12
(TRV > 2.8–2.9 msec: SPAP
36 mm Hg)
MPAP = TVITR + RAP
13
($25 mm Hg)
ATRVOT (<100 msec)
log10 (EPSPAP) = 0.004(PAAT)
+ 2.115
PVCAP = SV/4  (TRV2  PRV2)14
(<0.8 mL/mm Hg predicts
mortality in PAH patients)
RAP = IVC size and
collapsibility16 (>2.1 cm,
collapse < 50%:
RAP 15 mm Hg)
RV IVRT0 (by DTI; >65 msec: SPAP
> 40 mm Hg; <59 msec: RAP
> 8 mm Hg)
MPAP = 4  PRV2 + RAP17,18
($25 mm Hg)
MPAP = 0.61 SPAP + 2mmHg19 MPAP = 90  0.62  ATRVOT20
MPAP = 79  0.45  ATRVOT
DPAP = 4  (PRV ED)2 + RAP
PVR = TRV/TVIRVOT (cm)  10
+ 0.1621 (>0.2: PVR > 2 WU;
<0.15: normal PVR)
PVR = SPAP/(HR  TVIRVOT)22
(>0.076: indexed PVR > 15 RU)
FVERVOT
23 (midsystolic ‘‘notch’’)
PCWP = 1.9 + 1.24  E/E024
(E/E0 >15: PCWP > 15 mmHg)
LAVi25 (>31 mL/m2)
Impaired RV systolic function
TAPSE (<16 mm) Tei index: (IVRT + IVCT)/ET (>0.40
by PW Doppler; >0.55 by DTI)
3D RV EF (<44%)
RV FAC (<35%) RV LPSS26 ($19%)
S0-wave velocity by DTI
(<10 cm/sec)
AT, Acceleration time by PW Doppler; DPAP, diastolic PAP; DTI, Doppler tissue imaging; ED, end-diastole; EF, ejection fraction; EPSPAP, esti-
mated peak SPAP; FAC, fractional area change ([end-diastolic area end-systolic area]/end-diastolic area 100); FVE, Doppler flow velocity en-
velope;HR, heart rate;ET, ejection time; IVC, inferior vena cava; IVCT, isovolumic contraction time; IVRT, isovolumic relaxation time; LAVi, left atrial
volume index (increases the accuracy for estimation of PCWP when E/E0 is 8–13 in the gray zone); LPSS, longitudinal peak systolic strain; PAAT,
pulmonary artery acceleration time;PRV, peak pulmonary regurgitation velocity;PSAX, parasternal short-axis;PVCAP, pulmonary vascular capac-
itance; PW, pulsed-wave; RA, right atrial; RVOT, RV outflow tract; SV, stroke volume; TAPSE, tricuspid annular plane systolic excursion (M-mode
echocardiography); 3D, three-dimensional TVI, time-velocity integral.
Indirect 2D echocardiographic signs include RV hypertrophy (RV wall thickness > 5mm from the subcostal view), RV dilation (diameter > 42 mm at
the base, >35 mm at the midlevel, longitudinal > 86 mm), RA dilation (area > 18 cm2, minor-axis dimensions > 44 mm, major-axis dimensions >
53 mm), RVOT dilation (PSAX distal diameter > 27 mm at end-diastole), systolic flattening of the interventricular septum, LV eccentricity index
(>1 in systole 6 diastole), and pericardial effusion.
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wall levels) and LV filling (at the lateral mitral annular level) in
response to long-term targeted therapy.4,24,98,99Two-Dimensional Strain
Despite the lack of reproducibility and the paucity of data, ventricular
strain and torsion analysis (an easily obtained, cost-effective, objective,
angle-independent, noninvasive technique) has been implemented to
assess regional and global RV function as well as the impact of RV
pressure overload on ventricular interdependence and relative LV
performance.87-90,100-115
Puwanant et al.,116 using 2D speckle-tracking echocardiography in
a series of 44 patients with precapillary PH (88% with PAH), demon-
strated that chronic RV pressure overload directly affects RV longitu-
dinal systolic deformation and interventricular septal and LV
geometry. Furthermore, they noted a decreased LV torsion along
with an impairment of segmental longitudinal and circumferential
strain that was greater for the interventricular septum than for the
LV free wall.
In a cohort of 80 patients with PAH, Sachdev et al.82 reported sig-
nificantly decreased RV longitudinal peak systolic strain (15 6 5%)
and strain rate (0.80 6 0.29 sec1). Furthermore, RV free wall
strain worse than 12.5% was found to be associated with a greaterdegree of clinical deterioration within 6 months, and it also pre-
dicted 1-year, 2-year, 3-year, and 4-year mortality (unadjusted
1-year hazard ratio, 6.2; 95% CI, 2.1–22.3). After adjusting for
age, sex, PH cause, and functional class, patients had a 2.9-fold
higher rate of death per 5% absolute decline in RV free wall strain
at 1 year.
Recently, Haeck et al.,26 in a series of 142 patients with PH of
different etiologies (53 [37%] with PAH), observed that RV longi-
tudinal peak systolic strain ($19%) was significantly associated
with worse New York Heart Association functional class, lower tri-
cuspid annular plane systolic excursion, and all-cause mortality (37
patients died during a median follow-up period of 2.6 years)
(Figure 3).
However, further studies in larger populations are needed to con-
firm the incremental prognostic value of strain-based measures over
other well-established invasive and noninvasive predictive parameters
of mortality, considering the variety of PH etiologies and their under-
lying pathophysiologic mechanisms.1-3RT3DE
Accurate volume analysis independent of RV size and shape, without
foreshortened views and geometric assumptions, ensures the superi-
ority of RT3DE over conventional echocardiographic methods in
Figure 1 A young patient with IPAH. (A,B) Apical four-chamber and parasternal short-axis views, showing severe right ventricular
enlargement and dislocation of the interventricular septum (IVS) toward the left ventricle (LV). (C) Doppler tracing of TR, showing
severe PH (TRV >5 m/sec) (arrow). (D) Dilated inferior vena cava (IVC) from the subcostal view. RA, Right atrium; RV, right ventricle.
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magnetic resonance, RV volumes calculated from RT3DE showed
significantly better agreement and lower intraobserver and
interobserver variability than those calculated from 2D
echocardiography.120-122 On the basis of current evidence, the
combination of conventional 2D and Doppler methods with
RT3DE can be recommended for the evaluation of RV function in
various clinical settings. Grapsa et al.,123 in a homogeneous cohort of
60 consecutive patients with PAH, demonstrated that RVremodeling
(relative changes in mass, volumes, and ejection fraction) can be com-
prehensively assessed with both RT3DE and cardiac magnetic reso-
nance without intravenous contrast agents. Each imaging modality
provided a significant degree of accuracy and reproducibility, with car-
diac magnetic resonance being more reproducible for measurements
of ejection fraction and RV mass. The use of intravenous contrast
agents can further improve RV visualization, particularly in smaller
right ventricles. In addition, RT3DE enables unique views to better un-
derstand specific causes of PH (i.e., septal defects, complex congenital
pathology, left-sided valvular or ventricular heart disease) and to inves-
tigate RV functional and morphologic changes.124-127 In this regard,
Grapsa et al.127 evaluated 141 consecutive patients with PH (55 with
PAH, 32 with chronic thromboembolic disease, and 34 with PH sec-
ondary to mitral regurgitation) using RT3DE and demonstrated that
different causes of PH may lead to diverse RV remodeling, regardless
of RV systolic pressures at rest. They found that patients with PAH had
more dilated, hypertrophied, and poorly functioning right ventricles
compared with those with other forms of PH. This may be explained
by the inability of the right ventricle to adapt to the silent, prolonged,
irreversible, and pathophysiologic alterations of pulmonary vessels
(vasoconstriction, cell proliferation, and thrombosis) observed in
PAH.128 It should be also underlined that in patients with PAH, the
degree of right-heart dilation and dysfunction is a key determinant
of adverse clinical outcomes.1,2,14,77-82,129
Finally, the capability to complement RVassessment with geomet-
ric data on tricuspid valve tenting in TR secondary to PH confirms theunique value of RT3DE to comprehensively address right-heart struc-
ture and function in patients with PAH.127,130SCREENING FOR PULMONARY ARTERIAL HYPERTENSION:
THE PIVOTAL ROLE OF ECHOCARDIOGRAPHY
The substantial time delay from symptom onset to definite diagnosis
in PAH remains an unresolved issue. This has relevant clinical implica-
tions, especially when considering the better prognosis and response
to treatment with early detection of the disease (WHO class I or II,
6-min walk distance > 450 m, normal or mildly increased B-type
natriuretic peptide, no evidence of right-heart failure). Regular echo-
cardiographic screening of patients at high risk for PAH or with unex-
plained symptoms of fatigue or dyspnea is essential and provides an
overall good sensitivity and specificity.1,2,4
As discussed, symptomatic (WHO classes II–IV) and asymptom-
atic (WHO class I) patients at high risk for PAH, with exercise-
induced PH or transthoracic echocardiographic findings suggestive
of or consistent with PH should undergo RHC (the gold standard),
and possibly left-heart catheterization, to confirm the diagnosis and di-
rect treatment. In asymptomatic subjects at high risk for PAH (those
with known genetic mutations, first-degree relatives in a familial
PAH family, patients with systemic sclerosis, patients with congenital
shunts, patients with portal hypertension, or mildly symptomatic pa-
tients with human immunodeficiency virus infection), regular clinical
and echocardiographic screening (at yearly intervals) is warranted to
detect the disease at an early stage.1,2,4 An echocardiography-based
diagnostic algorithm is shown in Figure 4. After an initial comprehen-
sive clinical evaluation, the patient should undergo a resting or exer-
cise transthoracic echocardiographic examination to detect direct
and/or indirect signs of PH and to exclude left-heart disease or
CHD. Additional imaging and diagnostic laboratory tests should be
considered when secondary causes of PH are suspected on clinical
grounds. Finally, it is important to realize that PAH accounts for
Table 4 PAP response to exercise in patients at high risk for PAH
Study Associated disease n Age (y) Height (cm) Weight (kg) Exercise protocol
RAP estimate
(mm Hg) Baseline SPAP (mm Hg) Peak SPAP (mm Hg)
Himelman et al.
(1989)53
COPD 36 (15 female) 32–80 Supine bicycle (10 or 25
W/2 incr)
From IVC 46 6 20 (ctrl 22 6 4) 83 6 30 (ctrl 31 6 7)
Oelberg et al. (1998)54 Asymptomatic ASD 10 (4 women) 52.9 6 11.2 167 6 7 82 6 20 Upright bicycle (10 W/2 incr) From IVC 31 6 8 (ctrl 17 6 8) 51 6 10 (ctrl 19 6 8)
Gr€unig et al. (2000)55 HAPE-S 9 men 45 6 8 182 6 8 82 6 9 Supine bicycle (25 W/2 incr) Fixed value
(5 mm Hg)
28 6 4 (ctrl 27 6 4) 55 6 11 (ctrl 36 6 3)
Gr€unig et al. (2000)56 Relatives of IPAH
cases
52 Supine bicycle (25 W/2 incr) Fixed value 24 6 4 (NR); 23 6 3 (AR) 37 6 3 (NR); 56 6 11(AR)
Collins et al. (2006)57 Scleroderma 51 (49 women) 53.9 6 12.0 Treadmill (5.9 6 1.9 METs) Fixed value
(10 mm Hg)
24 6 8 38 6 12
Alkotob et al. (2006)58 Scleroderma 65 (56 women) 51 6 12 Treadmill (1 to 13.4 METs) Fixed value
(5 mm Hg)
25 6 8 39 6 8
Kiencke et al. (2008)59 HAPE-S 10 33 6 2 Supine bicycle 19 6 4 (ctrl 17 6 3) 23 6 6 (ctrl 11 6 5)
Steen et al. (2008)60 Scleroderma 54 (51 women) Treadmill (85% pred max HR) Fixed value
(10 mm Hg)
34.5 6 11.5 51.4
Gr€unig et al. (2009)48 Relatives of IPAH
patients
291 (125 women) 37 6 16 169 6 9 69 6 15 Supine bicycle (25 W/2 incr) From IVC 20.7 6 5.4 (ctrl 20.4 6 5.3) 39.5 6 5.6 (ctrl 35.5 6 5.4)
Reichenberger et al.
(2009)61
Scleroderma 33 (31 women) 54 6 11 Supine bicycle (30 W/2 incr) From IVC 23 6 8 40 6 11
M€oller et al. (2010)62 ASD and VSD 44 (25 female) 17.5 6 3.3 167 6 8.8 59 6 11 Supine bicycle (25 W/2 incr) From IVC 20.7 6 5.3 (ctrl 21.8 6 3.6) 37 (24–76) (ctrl 39 [17–63])
Kovacs et al. (2010)63 Connective tissue
disease
52 (42 women) 54 6 11 167 6 8 69 6 12 Supine bicycle (25W/2 incr) From IVC 27 6 5*; 23 6 3†; 23 6 3‡ 55 6 10*; 29 6 8†; 30 6 7‡
D’Alto et al. (2011)64 Systemic sclerosis 172 (155 women) 51.8 6 21.5 163 6 9 66 6 14 Supine bicycle (25W/2 incr) From IVC 26.2 6 5.3 (ctrl 20.6 6 3.7) 36.9 6 8.7 (ctrl 25.9 6 3.3)
AR, Abnormal response to exercise; ASD, atrial septal defect;COPD, chronic obstructive pulmonary disease; ctrl, controls;HAPE-S, high-altitude pulmonary edema susceptible;HR, heart
rate; incr, increments; IVC, inspiratory collapse of the inferior vena cava; NR, normal response to exercise; VSD, ventricular septal defect.
*Exercise SPAP > 40 mm Hg.
†Exercise SPAP < 40 mm Hg, peak oxygen uptake < 75%.
‡Exercise SPAP < 40 mm Hg, peak oxygen uptake > 75%.
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Table 5 Echocardiographic prognostic predictors in patients with PAH
Study Patients Age (y) Etiology Treatment
Echocardiographic
indices Follow-up (median) Outcome
Eysmann et al. (1989)75 26 (18 women) 40.8 PPH Vasodilators* Pericardial effusion 19.7 mo Death
Hinderliter et al. (1997)76 79 (57 women) PPH PGI Pericardial effusion 1 y Death, lung
transplantation
Yeo et al. (1998)77 53 (38 women) 45 6 14 PPH CCBs Tei index† $ 0.83 2.9 y Death, lung
transplantation
Raymond et al. (2002)78 81 (59 women) 40 6 15 PPH PGI Pericardial effusion, RA
area index (5 cm2/m)
1 y Death, lung
transplantation
Forfia et al. (2006)79 63 (52 women) 55 6 15 IPAH, SSc, CTD, RD,
CTEPH
PGI, ERA, PDE5-i
inhibitors
TAPSE < 1.8 cm 19.3 mo Death
Mahapatra et al. (2006)14 54 (41 women) 44 6 11 PPH PGI, ERA, CCBs PVCAP 49.3 mo Death
Brierre et al. (2010)80 79 (36 women) 61.4 IPAH, anorexigens, SSc,
IDD, portal
hypertension, HIV, RD,
CTEPH, sarcoidosis
ERA, PGI, PDE5-i
inhibitors, PEA
MPAP $ 49 mm Hg,
DPAP $ 29 mm Hg,
abnormal EDSC, IVC
diameter‡, Tei index†$
0.98, TAPSE§,
pericardial effusion
12 mo Death
Ghio et al. (2011)81 72 (52 women) 52 6 16 IPAH According to current
guidelines
RV diametersk (>36.5
mm)
38 mo Death
Sachdev et al. (2011)82 80 (61 women) 56 6 14 PAH According to current
guidelines
RV free wall strain per
absolute 5% decrease
24 mo Death
CCB, Calcium channel blocker; CTD, connective tissue disease; CTEPH, chronic thromboembolic pulmonary hypertension; DPAP, diastolic PAP as measured from pulmonary regurgitant
flow; ERA, endothelin receptor antagonist (bosentan); EDSC, end-diastolic septal curve, defined as abnormal if convex toward the right ventricle on the two-dimensional parasternal short-
axis view; HIV, human immunodeficiency virus; IDD, immune dysfunction disease; IVC, inferior vena cava; PDE5-i, phosphodiesterase type 5 inhibitor (sildenafil); PEA, pulmonary endar-
terectomy; PGI, prostacyclin and analogues (epoprostenol, iloprost, treprostinil); PPH, primary PH; PVCAP, pulmonary vascular capacitance; RA, right atrial; RD, respiratory disease; SSc,
systemic sclerosis (scleroderma); TAPSE, tricuspid annular plane systolic excursion.
*CCBs, prazosin, hydralazine.
†Tei index = (isovolumic contraction time + isovolumic relaxation time)/ejection time.
‡Twenty or more millimeters with respiratory variation in IVC diameter <50%.
§As a continuous variable for each 1-mm decrease.
kRV end-diastolic diameters (RV wall thickness # 6.6 mm) in the parasternal long-axis view.
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Figure 2 Impaired right ventricular function assessed by different echocardiographic techniques in a young patient with IPAH. (A)
Standard M-mode echocardiography: severely reduced tricuspid annular plane systolic excursion (arrow). (B) Pulsed-wave Doppler
tissue imaging of the right ventricular lateral wall: reduced myocardial systolic peak velocity (Sm) and both early (Em) and late (Am)
diastolic peak velocities. (C)Right ventricular 2D speckle strain: impairment of global longitudinal strain (GS) (<16%), an index of right
ventricular myocardial deformation, and of segmental myocardial deformation (see arrow showing longitudinal deformation curves of
six right ventricular myocardial segments). (D) Dynamic three-dimensional tripartite Beutel model (arrow), showing a dilated right
ventricle (RV) with depressed ejection fraction (22%). AVC, Aortic valve closure; RA, right atrium.
Figure 3 Kaplan-Meier survival curves in a PH population.
Kaplan-Meier survival curve for patients with RV longitudinal
peak systolic strain (LPSS) < 19% (solid line) and patients
with RV LPSS $ 19% (dotted line). During a median follow-
up period of 31.2 months (interquartile range, 10–50 months),
37 patients (26%) died. Patients with RV LPSS$19%had sig-
nificantly worse survival than those with RV LPSS < 19%.
Reproduced with permission from Haeck et al.26
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Bossone et al 9only 3% to 4% of all causes of PH, the vast majority being due to left-
heart (78%–80%) and/or lung (10%–12%) diseases.2RHC and Vasoreactivity Testing
RHC is required to confirm the diagnosis of PAH, to assess the se-
verity of hemodynamic impairment, and to test the vasoreactivity ofthe pulmonary circulation.2 The procedure has very low morbidity
(1.1%) and mortality (0.05%) rates if performed at experienced cen-
ters.131 It is usually performed through direct puncture of the right
internal jugular vein or the right or left femoral vein. The following
variables must be recorded during RHC: PAP (systolic, diastolic, and
mean), RAP, PCWP, and RV pressure. CO must be measured in
triplicate. Superior vena cava, pulmonary artery, and systemic arte-
rial blood oxygen saturation should also be determined. These mea-
surements are needed for the calculation of PVR. Satisfactory
recording of PCWP is crucial for the differential diagnosis of PH
due to left heart disease. PCWP > 15 mm Hg excludes the diagnosis
of precapillary PAH. Rarely, left-heart catheterization may be re-
quired for direct assessment of LV end-diastolic pressure. The Fick
method is mandatory in the presence of a systemic-to-pulmonary
shunt.
Vasoreactivity testing is strongly recommended at the time of RHC
in IPAH, heritable PAH, and PAH associated with anorexigen use to
identify patients who may benefit from long-term therapy with cal-
cium channel blockers (CCBs; nifedipine, diltiazem, and amlodi-
pine).132,133
Acute vasodilator challenge should be performed only at experi-
enced centers using short-acting and safe drugs with no or limited sys-
temic effects, such as inhaled nitric oxide (the preferred agent).
Alternatively, intravenous epoprostenol or adenosine may also be
used, but with a risk for systemic vasodilator effects.2
A positive acute response is defined as a reduction in MPAP $ 10
mm Hg to reach an absolute value of MPAP # 40 mm Hg with in-
creased or unchanged CO.2 Only about 10% of patients with IPAH
will meet these criteria. Approximately half of IPAH-positive acute re-
sponders are also positive long-term responders to CCBs,4 and only in
Symptoms/Signs/History suggestive of  PH  
 ECG - Chest X-ray - Routine biochemistry - BNP  
Bicycle exercise
†
TTE -Doppler
TTE
SPAP, MPAP, DPAP, RAP, additional indexes and 2D signs
Right  Heart Catheterization and Vasoreactivity 
Mean PAP  ≥  25mmHg; PCWP or PAOP   ≤  15mmHg, PVR >3RU 
HRCT 
+
Group 2 
PH due to 
LH disease
78.7%
Group 3 
PH due to 
lung disease
9.7%
Group 1 
IPAH,
FPAH, and 
associate
disease
4.2% 
Group 4 
CTEPH
0.6% 
Sx CTD 
HIV
ABS, SPO2 
Sleep study 
TEE CMR 
Abdominal US
Specific. 
Lab Test
PFT 
CT-angio PA-angio 
LFT 
PH likely**
Clinical picture
PCWP/PVR
PH possible*
Precapillary PH
LH systolic/diastolic 
dysfunction, LAE 
E/E  ratio >15 
Valvular disease
Group 1’
PVOD 
PCH
Uncommon
condition
V/Q scan HRCT 
V/Q scan 
Post-capillary PH
neg
Yearly follow-up for 
high probability 
SSc, SLE, 
MCTD, RA 
Congenital
heart disease 
Porto-PH
Anorexigen or 
Family Hx of PAH
Group 5 
PH with unclear and/or 
multifactorial mechanism 
ESRD on hemodialysis, 
splenectomy, thyroid 
disorders, sarcoidosis 
myeloproliferative disease, 
fibrosing mediastinitis 
6.8% 
Figure 4 Role of echocardiography in the diagnosis of PAH. ABG, Arterial blood gases or saturation; BNP, B-type natriuretic pep-
tide; CMR, cardiac magnetic resonance; CT-angio, contrast-enhanced computed tomographic pulmonary angiography; CTD,
connective tissue disease; CTEPH, chronic thromboembolic PH; DPAP, diastolic PAP; ECG, electrocardiography; ESRD, end-
stage renal disease; Fam Hx, family history; FPAH, familial PAH; HIV, human immunodeficiency virus; HRCT, high-resolution
computed tomography; LAE, left atrial enlargement; LFT, liver function test; LH, left heart; MCTD, mixed connective tissue
disease; neg, negative; PA-angio, pulmonary artery angiography; PAOP, pulmonary artery occlusion pressure; PCH, pulmonary
capillary hemangiomatosis; PFT, pulmonary function test (spirometry, diffusing capacity of the lungs for carbon monoxide, over-
night oximetry, polysomnography); Porto-PH, portopulmonary hypertension; PVOD, pulmonary veno-occlusive disease; RA,
rheumatoid arthritis; RU, resistance units; SLE, systemic lupus erythematosus; SPO2, saturation of peripheral oxygen; Sx, symp-
toms; SSc, systemic sclerosis; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography; US, ultrasound;
V/Q, ventilation/perfusion. aSpecific laboratory tests for thyroid function, immunology-rheumatology (antinuclear antibodies, C-
reactive protein, Scl-70 antibodies), hematology, HIV, and schistosomiasis. *TRV # 2.8 m/sec and SPAP # 36 mm Hg but
the presence of additional echocardiographic variables or TRV of 2.9 to 3.4 m/sec and SPAP of 37 to 50 mm Hg, with or without
additional echocardiographic variables suggestive of PH. **TRV > 3.4 m/sec and SPAP > 50 mm Hg, with or without additional
echocardiographic variables suggestive of PH.2 †Doppler upper limits: <40 to 45 mm Hg in healthy individuals, <55 to 60 mm Hg
in highly trained athletes; MPAP 34 mm Hg at a CO of <10 L/min, 45 mm Hg at a CO of <20 L/min, and 52 mm Hg at a CO of
<30 L/min.8,45,50
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Bossone et al 11these patients is the continuation of CCBs as a single therapy
reasonable.
The effectiveness of acute vasoreactivity tests and long-term treat-
ment with CCBs in patients with associated PAH is still debated. In
particular, the use of CCBs is not recommended in patients with
CHD-related PAH because of their negative inotropic and systemic
vasodilator effects (with subsequent increase in right-to-left shunting).
Recent observations suggest that residual pulmonary vasoreactivity
may be a valuable tool for the risk stratification of patients with CHD-
related PAH.134,135
Finally, acute vasoreactivity studies to identify patients with long-
term favorable responses to CCBs are not recommended in clinical
groups 2, 3, 4, and 5.CONCLUSIONS
Echocardiography is a pivotal screening test in symptomatic
patients at risk for PAH. As an imaging modality, it has the advan-
tage of being widely available, cost effective, and safe. It also plays
an important role in assessing outcomes, monitoring the efficacy of
specific therapeutic interventions for PH, and detecting the preclin-
ical stages of disease. Newer ultrasound techniques may provide
key additional information in the assessment of right-heart structure
and function.REFERENCES
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